K-BioSolution, a South Korean medical device developer, announced on June 8 that it has completed supplemental submissions for its monopolar radiofrequency (RF) skin aesthetic device and entered the final review stage for FDA 510(k) clearance. The news signals a potential new entrant in the U.S. aesthetic RF device market, relevant for distributors and clinics seeking FDA-cleared alternatives. Meanwhile, Sellemix secured $310 million to accelerate NGS and new business, and G2GBio presented preclinical data on long-acting obesity therapies at ADA 2026.
K-BioSolution: FDA 510(k) Final Stage for Monopolar RF Device
K-BioSolution has independently secured 14 FDA 510(k) clearances since its founding in 2016, without outsourcing to U.S. consultants. The company manages the entire process from submission to responding to deficiency letters, a strategy that reduces risk and improves approval rates. The monopolar RF device targets skin tightening by delivering heat energy to the dermis, stimulating collagen production and improving skin elasticity.
The company’s competitive edge includes rigorous animal testing designed to meet CDRH standards, minimizing supplemental requests. CEO Kang Kyung-yoon, a former FDA/EU/Asia regulatory director at Cardinal Health, St. Jude Medical, and Cook Medical, also leads MDR CE certification consulting, having achieved South Korea’s first Class III MDR CE certification and guided InBody’s body composition analyzer through MDR.
Sellemix: $310M Funding to Boost NGS Core and New Ventures
Sellemix, an NGS-based biotech firm, completed a $310 million fundraising round on May 29, including a $12 million third-party allotment and convertible bonds. The funds will first enhance its core NGS technology and profitability, with approximately $115 million allocated for acquiring stakes in other companies to fuel new business.
Notably, Dr. Deok-Ho Kim, a renowned biomedical engineering professor at Johns Hopkins University School of Medicine, participated via an investment fund, underscoring the technology’s global credibility. Internal executives, including the former CEO, also joined the offering, signaling strong confidence in the company’s vision.
G2GBio: Long-Acting Obesity Drug Platform Data at ADA 2026
G2GBio presented preclinical data at the American Diabetes Association (ADA) 2026 meeting in New Orleans, showcasing its InnoLAMP platform’s ability to formulate high-dose dual and triple agonists—cagrisema, tirzepatide, and retatrutide—into once-monthly injectables. These drugs have demonstrated over 20% weight loss in clinical trials, with retatrutide achieving 28.3%.
High drug loading (over 50% peptide content) is a key challenge for subcutaneous (SC) formulations. G2GBio’s InnoLAMP technology achieved less than 5% initial burst release within 24 hours and stable plasma drug levels for over 28 days in rodent studies, supporting a monthly dosing profile.
What buyers should watch
For aesthetic device distributors and clinics, K-BioSolution’s RF device, once cleared, could offer a cost-effective alternative in the U.S. monopolar RF market. The company’s proven FDA track record and in-house regulatory expertise reduce supply-chain risks. For obesity treatment stakeholders, G2GBio’s long-acting platform may enable more convenient dosing for high-demand GLP-1-based therapies, potentially impacting future injectable product availability.
Source: Read the original report | Published: June 08, 2026